Roche’s fenebrutinib cuts relapses in MS amid safety concerns
Roche is hoping to bring the the first and only high-efficacy oral for both relapsing multiple sclerosis (RMS)…
Roche fenebrutinib cuts RMS relapses 51%-59%
Roche (OTCQX: RHHBY) reported that investigational fenebrutinib met primary endpoints in Phase III…
Roche ENSPRYNG cuts MOGAD relapse risk 68%
Roche (OTCQX: RHHBY) reported Phase III METEOROID results showing ENSPRYNG (satralizumab) reduced risk…
Genentech persevERA breast cancer trial misses PFS goal
03/09/2026 –…
Genentech fenebrutinib slashes MS relapses 51%
03/02/2026 – 01:10 AM – FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by…
Roche lupus drug cuts disease activity in phase III
Roche (OTCQX: RHHBY) announced NEJM publication of phase III ALLEGORY data showing Gazyva/Gazyvaro (obinutuzumab) plus standard therapy significantly…
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
F. Hoffmann-La Roche Ltd persevERA Breast Cancer study did not meet the primary objective of a statistically significant…
Roche’s Giredestrant Misses Key Goal in First-Line Breast Cancer Study
Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients…
Roche’s Giredestrant Misses Key Goal in First-Line Breast Cancer Study
Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients…
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
F. Hoffmann-La Roche Ltd Basel, 13 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that…
Roche MS drug fenebrutinib cuts relapses 51% in Phase III
Roche (OTCQX: RHHBY) reported that the pivotal Phase III study FENhance 1 met…
Roche’s Gazyva Meets Phase III SLE Endpoints at 52 Weeks
Roche (RHHBY) announced on 3 November 2025 that the phase III ALLEGORY study…